Biotage AB (BIOT) - Total Liabilities
Based on the latest financial reports, Biotage AB (BIOT) has total liabilities worth Skr862.00 Million SEK (≈ $92.76 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore BIOT year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Biotage AB - Total Liabilities Trend (2000–2024)
This chart illustrates how Biotage AB's total liabilities have evolved over time, based on quarterly financial data. See Biotage AB (BIOT) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Biotage AB Competitors by Total Liabilities
The table below lists competitors of Biotage AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jinhui Liquor Co Ltd
SHG:603919
|
China | CN¥1.55 Billion |
|
CVR Partners LP
NYSE:UAN
|
USA | $706.44 Million |
|
Tekfen Holding AS
IS:TKFEN
|
Turkey | TL39.41 Billion |
|
Treehouse Foods Inc
NYSE:THS
|
USA | $2.51 Billion |
|
Grupo Televisa S.A.B.
F:TLV
|
Germany | €122.08 Billion |
|
Techno Electric & Engineering Company Limited
NSE:TECHNOE
|
India | Rs17.82 Billion |
|
Tourmaline Bio Inc.
NASDAQ:TRML
|
USA | $10.10 Million |
|
COSMO Pharmaceuticals SA
LSE:0RGI
|
UK | £143.35 Million |
Liability Composition Analysis (2000–2024)
This chart breaks down Biotage AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see BIOT market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.53 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.88 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.22 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biotage AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biotage AB (2000–2024)
The table below shows the annual total liabilities of Biotage AB from 2000 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr991.00 Million ≈ $106.65 Million |
-22.21% |
| 2023-12-31 | Skr1.27 Billion ≈ $137.10 Million |
+81.48% |
| 2022-12-31 | Skr702.00 Million ≈ $75.55 Million |
+13.23% |
| 2021-12-31 | Skr620.00 Million ≈ $66.72 Million |
+39.51% |
| 2020-12-31 | Skr444.40 Million ≈ $47.82 Million |
-3.43% |
| 2019-12-31 | Skr460.19 Million ≈ $49.52 Million |
+52.87% |
| 2018-12-31 | Skr301.02 Million ≈ $32.39 Million |
+102.59% |
| 2017-12-31 | Skr148.59 Million ≈ $15.99 Million |
+12.60% |
| 2016-12-31 | Skr131.96 Million ≈ $14.20 Million |
+8.01% |
| 2015-12-31 | Skr122.17 Million ≈ $13.15 Million |
+5.00% |
| 2014-12-31 | Skr116.36 Million ≈ $12.52 Million |
+0.77% |
| 2013-12-31 | Skr115.47 Million ≈ $12.43 Million |
-6.30% |
| 2012-12-31 | Skr123.24 Million ≈ $13.26 Million |
-8.81% |
| 2011-12-31 | Skr135.16 Million ≈ $14.55 Million |
+7.71% |
| 2010-12-31 | Skr125.48 Million ≈ $13.50 Million |
-9.31% |
| 2009-12-31 | Skr138.36 Million ≈ $14.89 Million |
-20.58% |
| 2008-12-31 | Skr174.22 Million ≈ $18.75 Million |
-9.42% |
| 2007-12-31 | Skr192.33 Million ≈ $20.70 Million |
-6.08% |
| 2006-12-31 | Skr204.79 Million ≈ $22.04 Million |
-13.40% |
| 2005-12-31 | Skr236.49 Million ≈ $25.45 Million |
+37.47% |
| 2004-12-31 | Skr172.03 Million ≈ $18.51 Million |
-20.78% |
| 2003-12-31 | Skr217.15 Million ≈ $23.37 Million |
+250.96% |
| 2002-12-31 | Skr61.88 Million ≈ $6.66 Million |
+0.07% |
| 2001-12-31 | Skr61.83 Million ≈ $6.65 Million |
+20.98% |
| 2000-12-31 | Skr51.11 Million ≈ $5.50 Million |
-- |
About Biotage AB
Biotage AB (publ) provides solutions and products in the areas of drug discovery and development, analytical testing, and water and environmental testing. The company offers organic and peptide synthesis solutions; flash chromotherapy, evaporation, parallel peptide purification, and work-up products; flash systems and accessories, and normal and reversed phase cartridges; sample preparation produ… Read more